Now let me run the calibration search to anchor the score.Initial bracket: **4.5 to 6.5**. The most directly comparable anchor is JQtuCumAFD.md (avg 5.50), the Davidov et al. predecessor paper. The paper under review adds counterfactual treatment prediction and improves coverage from PAC-type to (approximately) exact, which is meaningful but arguably incremental on the predecessor's framework. Let me narrow within the bracket.Now I have enough to write the full review. Let me compile all findings.

---

## Summary

This paper introduces *conformalized survival counterfactual prediction*, a calibration procedure for constructing lower predictive bounds (LPBs) on counterfactual survival times under general right-censored data. The key mechanism restricts calibration to uncensored treated observations and reweights the resulting conformal scores via the inverse probability of being in treatment group *w* and uncensored, reducing the problem to weighted conformal prediction (Lei & Candès, 2021). The paper claims this yields an *exact* marginal coverage guarantee — as opposed to the PAC-type guarantees of the direct predecessors (Gui et al., 2024; Davidov et al., 2025) — and additionally proves a doubly robust property. Experiments on six synthetic settings and a real lung cancer dataset support the approach.

---

## Strengths

1. **Genuine advance over prior coverage type**: The distinction between marginal coverage (this paper) and PAC-type coverage (Davidov et al., 2025) is real and non-trivial. PAC-type bounds control the probability that coverage holds over calibration randomness, meaning expected miscoverage can still fall below the nominal level. The present paper's approach controls the expected miscoverage rate directly (up to a weight estimation error term), which is strictly more informative for clinical use-cases. Equation (1) shows this explicitly via the upper bound chain (i)–(iv).

2. **Doubly robust property (Theorem 4.2)**: The paper proves that asymptotic coverage is maintained if either the weight function $\hat{\gamma}(x)$ or the counterfactual quantile estimator $\hat{q}_\alpha^{(w)}(x)$ is consistently estimated. This guards against model misspecification in a way not previously established for survival counterfactual prediction. Assumptions A1 and A2 capture two distinct robustness paths.

3. **Robustness to outliers**: Figure 3 shows a meaningful empirical advantage — the Focus and Fused baselines (PAC-type) systematically lose marginal coverage when survival time outliers are introduced, while the proposed method maintains coverage near 90%. This directly validates the theoretical advantage of marginal vs. PAC-type guarantees in practice.

4. **Informative LPBs with more power than baselines**: Across settings 3, 4, and 5 in Figure 1, the proposed method achieves the highest relative LPB among methods that satisfy coverage, i.e., it is less conservative. Table 1 and Figure 11 show the τ-optimization procedure yields materially higher LPBs compared to the default τ = α.

5. **Clinically grounded real-data analysis**: The application to 541 NSCLC patients (Section 5.2) demonstrates that the LPBs align with established clinical evidence across radiotherapy and chemotherapy regimens (Figure 4) and respond correctly to known prognostic factors including staging, KPS, and radiomic features (Figure 5).

---

## Weaknesses

### Fatal
None.

### Major

- **"Exact" coverage label is misleading and requires correction**: Theorem 4.1 (Equation 4) delivers:
  $$\mathbb{P}(T(w) \geq \tilde{L}) \geq 1 - \alpha - \tfrac{1}{2}\,\mathbb{E}|\tilde{\omega}(X) - \omega(X)|,$$
  where the second term is the L1 estimation error of the reweighting function. This is *not* an exact guarantee — it is an approximate bound whose slack depends on weight estimation quality. The paper uses the word "exact" in the abstract, introduction, contributions list (line 33), and Section 4.2, but this description applies only to the oracle case of known weights. Theorem 4.2 gives only *asymptotic* validity under consistent estimation, not finite-sample exactness. The paper does acknowledge the weight estimation dependency in Section 4.2 ("This bound quantifies how estimation error in the density ratio affects the coverage probability") and in the Discussion, but this acknowledgment is buried and never reconciles with the "exact" framing that dominates the paper. This misrepresentation could mislead readers about the conditions of validity. The correct framing is: "marginal coverage is guaranteed up to an L1 weight estimation error term, which vanishes under consistent estimation." This should be corrected throughout the manuscript.

- **Setting 6 empirical undercoverage is unexplained**: The paper acknowledges that "the average coverage rate of our method slightly falls below 1 − α in setting 6" (Section 5.1). Since coverage is the paper's primary guarantee, undercoverage in one of six test settings needs a clear explanation. The characteristics of Setting 6 (censoring rate, treatment imbalance, distributional form) are relegated to Appendix C.1, which the main text does not summarize. Without this explanation, the reader cannot determine whether Setting 6 represents a narrow edge case or a commonly occurring clinical scenario. If Setting 6 involves high censoring or severe treatment imbalance, this connects to the weight estimation error in Theorem 4.1 and should be used to illustrate the bound's slack in practice.

### Minor

- **Effective sample size under high censoring is not analyzed**: Algorithm 1 Step 3 restricts calibration to $\mathcal{I}_{\text{cal}}^{(w)} = \{i : W_i = w, e_i = 1\}$. In high-censoring clinical settings — the paper's primary motivation — this can reduce usable calibration data substantially (e.g., 60% censoring × 40% treatment assignment ≈ 16% utilization). The paper mentions in the Discussion that high censoring rates may lead to inaccurate γ(x) estimation, but provides no empirical analysis of how coverage quality or LPB informativeness varies with censoring rate. An analysis of coverage versus censoring rate would directly characterize the method's operating range.

- **τ optimization and calibration data independence**: The LPB is maximized over τ per test point (Section 4.1, Equation 3). Since the paper guarantees coverage for *any* τ, selecting the best τ post-hoc is valid in principle. However, it is not fully specified whether τ is selected using the same calibration data that determines $c_{1-\alpha}^{(w)}(\tau)$. If so, this introduces a dependence that could affect the bound in small samples. The use of a separate validation fold (Step 2 mentions training/calibration split, but validation for τ is not explicitly separated) should be clarified.

- **Cross-treatment LPB comparison overstates causal interpretation**: Section 5.2 concludes "higher median LPB under VMAT than IMRT, consistent with VMAT's better clinical benefits." While this is framed as consistent with prior evidence, LPB magnitude comparisons across treatment groups are not direct treatment effect estimates: a larger LPB under VMAT could partially reflect patient selection even with reweighting, since the paper's guarantee is for marginal coverage, not treatment effect identification. The Discussion should note this interpretive limitation.

### Trivial
None identified.

---

## Nice-to-Haves

- An empirical study of coverage rate and LPB informativeness as a function of censoring rate (e.g., varying from 20% to 80%) would directly demonstrate the method's practical operating range and is more valuable than the additional sensitivity analyses already in the appendix.
- A formal proposition comparing the paper's guarantee to the PAC-type bound — showing under what conditions the expected-miscoverage control strictly dominates high-probability-over-calibration control — would make the theoretical advantage more concrete.
- Candès et al. (2023) is cited as the seminal predecessor but does not appear in numerical comparisons. A brief discussion of why Type-I censoring restriction makes direct comparison infeasible (with a footnote in Section 5.1) would preempt reviewer questions.

---

## Removed Points
*These points were flagged for removal — treat them with caution:*

- **Strawman about Theorem 4.2 Condition A2(ii) being non-standard**: The harsh critic flags that condition A2(ii) (lim$_{N\to\infty}[\mathcal{E}_N(X)/\hat{\gamma}(x)] = \lim_{N\to\infty}[\mathcal{E}_N(X)/\gamma(x)]$) does not cleanly match the "doubly robust" intuition. This is a theoretical precision concern in a condition that governs an asymptotic regime. It is a legitimate nitpick but does not invalidate the theorem or the paper's contribution — removed as trivial.

- **Missing censoring rate details for six synthetic settings**: The harsh critic says these are "relegated to Appendix C.1 (stripped by the parser)." Per hard rules, appendix contents are not absent in the original; this parser artifact cannot be used as evidence of a flaw.

- **Request for Candès et al. (2023) as a numerical baseline**: Their method is Type-I restricted and explicitly inapplicable to the general right-censored setting studied here. The asymmetric comparison would favor baselines, not the authors. Removed per the relevant hard rule.

- **Strength: "Clinically meaningful real-data analysis" demonstrates treatment superiority**: This strength partially conflicts with the minor weakness about over-interpreting cross-treatment LPB comparisons. Retained as a valid strength with the note that interpretive scope is limited.

- **Strength Finder item about τ-selection "optimized LPB is comparable to τ=α" as a pure strength**: This is a double-edged observation — if optimal τ ≈ α, the τ optimization adds little. It remains useful evidence that the quantile model is calibrated, but is not a strong selling point.

---

## Novel Insights

The most technically interesting observation in these reviews (confirmed by the paper) is the structural connection between PAC-type and marginal coverage guarantees in the presence of outliers: Figure 3 makes visible that PAC-type guarantees (Focus, Fused) collapse empirically under distributional contamination, while the proposed marginal guarantee remains robust. This empirical demonstration is more compelling than the theoretical distinction alone and provides a concrete operational argument for preferring marginal over PAC guarantees in clinical settings where patient populations are heterogeneous and tails matter. The paper understates this contribution relative to the theoretical framing it devotes most of its attention to.

---

## Suggestions

1. **Replace "exact" throughout with "marginal" or "expected-miscoverage-controlled"**: Specifically, every instance of "exact miscoverage guarantee" should be replaced with language acknowledging the L1 weight estimation error term from Theorem 4.1. The distinction from PAC-type guarantees is genuine and compelling — it does not need to be overstated to be publishable.
2. **Address Setting 6 in the main text**: Add a brief characterization of Setting 6's data properties and explain what causes the slight undercoverage (likely high censoring or poor weight estimation). This is essential transparency given that coverage is the headline guarantee.
3. **Add a censoring rate sensitivity analysis**: Vary censoring rate from low (20%) to high (80%) and report both coverage and LPB quality. This is the single most informative experiment missing from the paper given the clinical motivation.
4. **Clarify τ optimization data pipeline**: Explicitly state whether a separate validation set is used for τ optimization or whether calibration data serves double duty. If the latter, note the potential finite-sample bias.

---

## Score and Decision

**Calibration anchors (all rounds):**

| Path | Avg Score | Round | Comparison |
|---|---|---|---|
| JQtuCumAFD.md | 5.50 | 1 & 2 | Direct predecessor (Davidov et al.). Paper under review extends to counterfactual + marginal coverage; comparable increment |
| pVL4bYKOGM.md | 5.50 | 1 & 2 | Conformal prediction for causal continuous treatments. Rejected. Similar conceptual extension but no survival specialization |
| AKAz88zYLB.md | 5.80 | 1 & 2 | Conformal + dose-response with propensity. Rejected. Similar use of weighted CP for causal inference |
| Nfd7z9d6Bb.md | 6.00 | 2 | Marginal → approximate conditional coverage move. Accepted. Similar guarantee-level improvement; cleaner framing |
| Bt1vnCnAVS.md | 6.25 | 2 | LOO-stable conformal prediction. Accepted. Stronger methodological novelty |
| RcNzwKrjTo.md | 5.00 | 2 | Conformal with improved conditional coverage. Rejected. |

**Round 1 bracket: 4.5–6.5**

**Round 2 narrowing:** The paper's contribution sits between JQtuCumAFD.md (5.50, accepted) and Nfd7z9d6Bb.md (6.00, accepted). Against JQtuCumAFD: the paper being reviewed extends the predecessor with counterfactual prediction (genuinely new problem) and improves coverage type, but adds the misleading "exact" framing, Setting 6 empirical shortfall, and absence of a censoring sensitivity analysis. Against Nfd7z9d6Bb.md: that paper achieves a cleaner guarantee with well-calibrated framing and gets 6.0. The paper under review is comparable in contribution magnitude but weaker in presentation precision. Against rejected anchors (pVL4bYKOGM, AKAz88zYLB at 5.50–5.80): both were rejected for incremental or sparse experimental validation; the paper here has more thorough experiments and a more self-contained application. 

The paper is stronger than the rejected 5.5-anchors due to more complete experiments and real-data validation, roughly comparable to JQtuCumAFD.md (accepted, 5.50) with an additional but incremental contribution layer. The "exact" framing issue is a major presentation problem but not a fundamental soundness flaw. Setting 6 undercoverage is minor. Final score: **5.5**.

**Originality**: Moderate. The core machinery (weighted conformal, quantile regression, doubly robust) is assembled from existing components; the novelty is in applying them to the counterfactual survival setting with a better coverage type. The combination is new but each piece is from prior literature.

**Importance**: Moderate-high. Counterfactual survival prediction with valid guarantees is a clinically relevant problem where prior work had genuine gaps.

**Claims vs. evidence**: Mostly well-supported, with the "exact" label being the main gap between claim and evidence.

**Soundness of experiments**: Adequate — six synthetic settings, outlier robustness, real data with prognostic validation. Setting 6 undercoverage is unexplained but minor.

**Clarity**: Clear overall but the coverage guarantee framing needs correction.

**Value to community**: Genuine incremental advance over Davidov et al. (2025) and fills the counterfactual treatment gap.

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Accept</decision>